NINDS Funding Strategy Fiscal Year 2023

Operations Under a Continuing Resolution

The Department of Health and Human Services (HHS), including NIH, is operating under the “Continuing Appropriations and Ukraine Supplemental Appropriations Act” (Public Law 117-180) signed by President Biden on September 30, 2022. This Act (CR) continues government operations through December 16, 2022 at the Fiscal Year (FY) 2022 enacted level.

Consistent with 
NIH procedures identified under NOT-OD-23-005 and during recent CRs, the NIH will issue non-competing research grant awards at a level below that indicated on the most recent Notice of Award (generally up to 90% of the previously committed level). After FY 2023 appropriations are enacted, NIH intends to adjust the awarded levels to 100% of the previously committed level, as it has done in previous years. However, as this upward adjustment is dependent on the 2023 budget level, NIH expects institutions to monitor their expenditures carefully during this period.

The table below describes the paylines for different categories of competing applications (i.e., new and renewal) during the period of the CR. Unless otherwise indicated, these paylines apply to the following types of applications: R01, R03, R15, and R21. Applications within these paylines will be funded with rare, NANDS Council-approved exceptions. These paylines may be adjusted when the FY 2023 appropriation is enacted:

Investigators  General Pay Line
All Investigators 14%
Early Stage Investigators (ESI)* 25% (R01s only)

*For an Early Stage Investigator (ESI) submitting Multi-PI Applications, all PIs on the application must be ESIs to receive the payline advantage. Additionally, ESI applications will be funded through the 25th percentile unless there are significant concerns. Some examples of such concerns can include: lack of independence of and/or appropriate resources for the PI, lack of scientific rigor in the proposed project, or substantial overlap with another funded project from the PI.

 

The policies outlined in the FY22 Funding Strategy also apply to FY23, unless otherwise stated.